A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL)

计划入组 30 人 · 首次发布于 2025 年 10 月 9 日

Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors

计划入组 304 人 · 首次发布于 2021 年 8 月 16 日

Monoclonal Antibody-based Multipurpose Microbicides

计划入组 36 人 · 首次发布于 2013 年 5 月 21 日

Recombinant humanized anti-CCR8 monoclonal antibody (Zai Lab)

Anti-CCR8 antibody(Hengrui)

anti-CCR8 antibody (solid tumors)

Cambridge Antibody Technology

New Zealand

Latticon Antibody Therapeutics, Inc

United States

Celltrion, Inc.

South Korea

Coherus Oncology Publishes Promising Data on CCR8-Targeting Antibody Tagmokitug for Solid Tumors

Domain Therapeutics Initiates First-in-Human Trial of DT-7012 Anti-CCR8 Antibody for Advanced Solid Tumors

SBP Group's M701 Bispecific Antibody Receives NDA Acceptance for Malignant Ascites Treatment